NCT06948955 2026-04-02
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Available
Clinical Trials
53 trialsNCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT07399015 2026-02-18
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
Endevica Bio
No longer available
NCT06195514 2026-01-30
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
Takeda
No longer available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT06910137 2026-01-08
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
Incyte Corporation
Available
NCT07319910 2026-01-06
PANOVA-3CA
NovoCure Ltd.
Temporarily not available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04087889 2025-09-29
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Hope Biosciences Research Foundation
No longer available
NCT04681248 2025-08-03
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Leap Therapeutics, Inc.
No longer available
NCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT03493152 2025-05-28
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
The University of Texas Health Science Center at San Antonio
No longer available
NCT04578444 2025-05-25
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Jazz Pharmaceuticals
No longer available
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT04087876 2025-04-06
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Basilea Pharmaceutica
No longer available
NCT03414489 2025-03-18
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
RedHill Biopharma Limited
No longer available
NCT05683548 2025-02-17
RCAP
Replicor Inc.
No longer available
NCT04948398 2025-02-03
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Janssen Research & Development, LLC
No longer available
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT02065765 2025-01-09
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Eli Lilly and Company
Approved for marketing
NCT02307812 2025-01-09
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Eli Lilly and Company
Approved for marketing
NCT06751524 2024-12-30
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT02286492 2024-09-05
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Taiho Oncology, Inc.
Approved for marketing
NCT06370013 2024-04-17
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Available
NCT05683470 2024-02-21
Expanded Access RBS2418 Treatment
Riboscience, LLC.
No longer available
NCT04446793 2024-02-12
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology
No longer available
NCT00906984 2024-01-08
TheraSphere
University of California, Irvine
Approved for marketing
NCT05274204 2023-02-27
Individual Patient Expanded Access to CA102N
Holy Stone Healthcare Co., Ltd
Temporarily not available
NCT02960620 2022-09-28
Therasphere for Unresectable Primary or Secondary Liver Neoplasia
H. Lee Moffitt Cancer Center and Research Institute
No longer available
NCT04132882 2021-09-16
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
TRPHARM
Available
NCT02449135 2021-09-09
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma
Fuda Cancer Hospital, Guangzhou
No longer available
NCT01076517 2021-04-01
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Stanford University
Approved for marketing
NCT04137822 2020-08-14
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Impatients N.V. trading as myTomorrows
No longer available
NCT01480128 2020-06-19
SIMPLE
The Catholic University of Korea
Approved for marketing
NCT04148092 2020-05-29
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Deciphera Pharmaceuticals, LLC
Approved for marketing
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT02436044 2019-08-20
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Sun Yat-sen University
Approved for marketing
NCT01538680 2019-05-29
CONSIGN
Bayer
No longer available
NCT02564224 2018-06-06
PURSE
Zhejiang University
No longer available
NCT00701168 2017-08-23
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
Leo W. Jenkins Cancer Center
No longer available
NCT00589030 2017-02-15
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
City of Hope Medical Center
No longer available
NCT01689376 2016-08-16
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Bayer
No longer available
NCT01613053 2015-04-24
MACS2226
Novartis
No longer available
NCT01646593 2014-12-15
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
Bayer
No longer available
NCT02209441 2014-08-06
Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
ChineseAMS
Available
NCT02082691 2014-03-10
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
The University of Texas Health Science Center at San Antonio
No longer available
NCT01728051 2013-10-23
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
Delcath Systems Inc.
No longer available